Alkem Laboratories Limited (NSE:ALKEM)
5,434.00
+40.50 (0.75%)
Sep 12, 2025, 11:30 AM IST
Alkem Laboratories Revenue
Alkem Laboratories had revenue of 33.71B INR in the quarter ending June 30, 2025, with 11.19% growth. This brings the company's revenue in the last twelve months to 133.04B, up 4.49% year-over-year. In the fiscal year ending March 31, 2025, Alkem Laboratories had annual revenue of 129.65B with 2.34% growth.
Revenue (ttm)
133.04B
Revenue Growth
+4.49%
P/S Ratio
4.85
Revenue / Employee
7.08M
Employees
18,785
Market Cap
644.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 129.65B | 2.97B | 2.34% |
Mar 31, 2024 | 126.68B | 10.68B | 9.21% |
Mar 31, 2023 | 115.99B | 9.65B | 9.08% |
Mar 31, 2022 | 106.34B | 17.69B | 19.96% |
Mar 31, 2021 | 88.65B | 5.21B | 6.24% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Aurobindo Pharma | 320.25B |
Alkem Laboratories News
- 21 days ago - Stocks to watch on August 22: Key brokerage calls on cement, GMR Airports, Wipro, autos, Alkem Labs, Reliance, and HAL - Business Upturn
- 21 days ago - Nomura raises target price on Alkem Labs, says valuation attractive on domestic growth and Enzene prospects - Business Upturn
- 4 weeks ago - Alkem Labs shares jump 4% as Nomura maintains ‘Buy’ rating with Rs 5,430 target after strong Q1 results - Business Upturn
- 4 weeks ago - Stocks to watch on brokerages’ radar today, August 13: Minda Corp, Apollo Hospitals, Alkem Labs, Nykaa, Zydus Lifesciences, HAL, ONGC, NHPC, Honasa, Paytm - Business Upturn
- 4 weeks ago - Alkem Laboratories shares jump 6% on strong Q1 results - Business Upturn
- 4 weeks ago - Alkem Laboratories Q1 Results: Revenue jumps 11.2% YoY to Rs 3,371 crore, net profit up Rs 21.45% YoY - Business Upturn
- 3 months ago - Alkem Labs shares trade lower after Rs 856 crore block deal - Business Upturn
- 3 months ago - Alkem Labs in focus as promoter Jayanti Sinha to sell 1.42 percent stake via Rs 825 crore block deal - Business Upturn